The evolution of SARS-CoV-2

PV Markov, M Ghafari, M Beer, K Lythgoe… - Nature Reviews …, 2023 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

[HTML][HTML] Mechanisms of SARS-CoV-2 entry into cells

CB Jackson, M Farzan, B Chen, H Choe - Nature reviews Molecular …, 2022 - nature.com
The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

[HTML][HTML] Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2

P Han, L Li, S Liu, Q Wang, D Zhang, Z Xu, P Han, X Li… - Cell, 2022 - cell.com
Summary The coronavirus disease 2019 (COVID-19) pandemic continues worldwide with
many variants arising, some of which are variants of concern (VOCs). A recent VOC, omicron …

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

D Cromer, M Steain, A Reynaldi, TE Schlub… - The Lancet …, 2022 - thelancet.com
Summary Background Several SARS-CoV-2 variants of concern have been identified that
partly escape serum neutralisation elicited by current vaccines. Studies have also shown …

The biological and clinical significance of emerging SARS-CoV-2 variants

K Tao, PL Tzou, J Nouhin, RK Gupta… - Nature Reviews …, 2021 - nature.com
The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Homologous and heterologous Covid-19 booster vaccinations

RL Atmar, KE Lyke, ME Deming… - … England Journal of …, 2022 - Mass Medical Soc
Background Although the three vaccines against coronavirus disease 2019 (Covid-19) that
have received emergency use authorization in the United States are highly effective …

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

PB Gilbert, DC Montefiori, AB McDermott, Y Fong… - Science, 2022 - science.org
In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …

SARS-CoV-2 variants, vaccines, and host immunity

P Mistry, F Barmania, J Mellet, K Peta… - Frontiers in …, 2022 - frontiersin.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new beta coronavirus
that emerged at the end of 2019 in the Hubei province of China. SARS-CoV-2 causes …

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

A Choi, M Koch, K Wu, L Chu, LZ Ma, A Hill, N Nunna… - Nature medicine, 2021 - nature.com
The emergence of SARS-CoV-2 variants of concern (VOCs) and variants of interest (VOIs)
with decreased susceptibility to neutralization has generated interest in assessments of …